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Abstract:  
 
Aims: First Episode Psychosis (FEP) patients who use cannabis experience 
more frequent psychotic and euphoric intoxication experiences compared to 
controls. It is not clear whether this is consequent to patients being more 
vulnerable to  the effects of cannabis use or to their heavier pattern of use. 
We aimed to determine whether extent of use predicted psychotic-like and 
euphoric intoxication experiences in FEP patients and controls and whether 
this differs between groups.  
 
Methods: We analysed data on lifetime cannabis using patients (n=655) and 
controls (n=654) across 15 sites from six countries in the EU-GEI study 
(2010-2015). We used multiple regression to model predictors of cannabis-
induced experiences and to determine if there was an interaction between 
caseness and extent of use. 
 
Results: Caseness, frequency of cannabis use and money spent on cannabis 
predicted psychotic-like and euphoric experiences, independent of other 
experiences (p≤0.001).  For psychotic-like experiences there was a significant 
interaction for caseness x frequency of use (p<0.001) and caseness x money 
spent on cannabis (p=0.001) such that FEP patients had increased 
experiences at increased levels of use compared to controls. There was no 
similar significant interaction for euphoric experiences (p>0.5). 
 
Conclusions and Relevance: FEP patients are particularly sensitive to 
increased psychotic-like, but not euphoric experiences, at higher frequency 
and amount of cannabis use compared to controls. This suggests a specific 
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psychotomimetic response in patients related particularly to heavy cannabis 
use.  
 
Keywords: schizophrenia, psychotic-like experiences, psychotomimetic, 
substance abuse 
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Association of extent of cannabis use and psychotic like 
intoxication experiences in a multi-national sample of First 
Episode Psychosis patients and controls 
 
Introduction 
There is consistent evidence supporting  an association between cannabis 
use and later psychosis(1). Further,  patterns of cannabis use in  first episode 
psychosis (FEP) patients are greater in terms of quantity, frequency and 
potency of cannabis used compared to controls from the same 
population(2,3). There is converging evidence that cannabis is a component 
cause of psychotic disorder with well-replicated evidence of dose-response 
effects on psychotic outcomes(3–6). 
 
When discussing psychosis and cannabis use, it is important to differentiate 
between psychotic-like experiences (PEs) and clinical psychotic disorder. 
Clinical psychotic disorder is relatively rare whereas PEs are common and 
self-limiting but can be a harbinger of more serious disorder(7,8). However, 
the usual instruments for measuring PEs, such as the Peter’s Delusions 
Inventory (PDI) or the Community Assessment of Psychic Experience 
(CAPE), either do not specifically index drug-induced experiences as  part of 
the intoxication state(9) or specifically exclude them(10,11).  
 
Recreational drugs such as cannabis are used primarily for their immediate 
psychoactive effects. Factor analytic approaches have clustered cannabis 
intoxication experiences into psychotic-like experiences (cPLEs) and euphoric 
experiences (cEEs)(12,13). cPLEs (sometimes called psychotomimetic 
experiences) are worthy of study in their own right as a model for psychotic 
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disorder. cPLEs are increased in patients versus controls(14,15); increased in 
those with schizotypy and those at risk of schizophrenia(13,16,17). cPLEs 
may predict cessation of use in a non-clinical sample(18)  whereas patients 
with psychotic disorders report using cannabis for affect regulation and 
socialization, despite awareness that cannabis has a detrimental effect on 
positive symptoms of psychosis(19).  
 
One study to date has reported that patients experience both cPLEs and 
cEEs more frequently than controls but this did not take into account 
increased use in patients(15).   Given that both increased rates of cannabis 
use and increased cannabis experiences are seen in FEP, it is not yet clear 
how these relate to each other and whether this differs from that of controls. 
No study to date has examined specifically the relationship between extent of 
use, cannabis experiences and psychotic disorder. 
 
We therefore studied cannabis experiences in a large international sample of 
FEP patients and control lifetime cannabis users. We hypothesised that: (a) 
we would replicate the finding of increased cPLEs and cEEs in FEP patients 
versus controls; (b) extent of use (as indexed by frequency of use, money 
spent on cannabis, and potency) would be associated with more frequent 
cannabis-induced experiences when adjusted for confounders; and (c) this 
effect would differ between cases and controls: specifically that both cPLEs 
and cEEs would be more affected by heavy use in FEP patients versus 
controls. We included THC potency as a proxy of the dose of Δ -
tetrahydrocannabinol the primary psychomimetic constituent in cannabis(20). 
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Methods: 
 
The European network of national networks studying gene environment 
interactions in schizophrenia (EU-GEI) study is a multi-centre study 
comprising several work packages(21). Workpackage 2 comprises a 17 
centre study across six countries (United Kingdom, Holland, Spain, France, 
Italy,  Brazil) on first episode psychosis. Local Research Ethics Committee 
approval was obtained from each area. 
 
Sample selection: Patients and controls were recruited between May 2010 
and May 2015. Patients were identified by trained EUGEI researchers across 
the 17 sites and invited by clinical teams to participate. For patients inclusion 
criteria were: (i) age 18-64; (ii) presentation with First Episode psychosis (ICD-
10 F20-33); and (iii) residence within each defined locality. Exclusion Criteria 
were: (i) organic psychosis (ICD-10: F09); (ii) psychosis due to acute 
intoxication (ICD-10: F1X.5) and (iii) previous contact with mental health 
services for psychosis.  
 
Controls were recruited using a quota strategy derived from local 
demographic data to be representative for age, sex and ethnicity of the 
population at risk for each site. In order to sample controls in the first instance 
we undertook random sampling a) from lists of all postal addresses and b) from 
GP lists from randomly selected surgeries. The EUGEI study aimed to over-
sample certain groups (e.g. young men) using direct approaches such as local 
avertismenets and leaflets at local shops and community centers. Controls were 
excluded if they had received a diagnosis or treatment for psychotic disorder.  
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Further details of the EUGEI study have previously been described(22). For 
the purpose of this study, analysing cannabis experiences, we only analysed 
data from participants (both patients and controls) who reported having ever 
used cannabis (lifetime use). 
 
We did not use data from two centres: Maison-Blanche (France) as this centre 
did not collect controls and Verona (Italy) as cannabis use data were not 
complete. We excluded 12 cases (1.8%) who were classified as having non-
psychotic illness from the Diagnosis and Statistical Manual IV (DSM-IV) 
Operational Criteria Checklist (OPCRIT) screening of medical records. 
 
Measures:  
Demographics: data were collected on age, sex, ethnicity, site, country and 
years of education.  
Cannabis use: A modified version of the Cannabis Experiences Questionnaire 
was used to collect cannabis use variables and cannabis experiences 
data(23). This is a researcher administrated measure which collects self-
reported data on: age of first use, frequency of use (categories: every day; 
more than once a week; a few times a month; a few times each year; only 
once or twice), average money spent in a week (categories: less than €2.50; 
€2.50-€5.00; €5.00-€10.00, €11.00-€15.00; €16.00-€20.00; and 6 above €20). 
Since there is geographical variation in type of cannabis used strain data was 
dichotomised into ‘high potency’ preparations (THC>10%) and ‘low potency’. 
using published data on the expected concentration of Delta-9-tetra-
hydrocannabinol (THC) in the different types of cannabis available across the 
sites(24). 
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Other drug use:  We collected data on number of other drugs used, number of 
cigarettes smoked per day and units of alcohol consumed daily.  
Cannabis Experiences: Frequency of nine intoxication experiences - six 
cPLEs (feeling fearful; feeling crazy or mad; feeling nervy; feeling suspicious; 
hearing voices; seeing visions); and three cEEs (feeling happy; understanding 
the world better; being full of plans or ideas) were rated on a 5 point Likert 
scale: (0 rarely or never, 1 from time to time, 2 sometimes 3 more often than 
not, 4 almost always). These experiences were chosen as previous factor 
analytic approaches in development of the Cannabis Experiences 
Questionnaire showed that these experiences load significantly onto 
respective subscales to index psychotic-like experiences and pleasurable 
effects(16,25).  
 
Statistical Analysis: Scores were obtained for cPLEs and cEEs by simple 
summation, as previously undertaken(18,23). As there were half as many 
euphoric experiences items as psychotic like experiences items, the scores 
for euphoric experiences were doubled rendering a scale of between 0 and 24 
for both cPLEs and cEEs. Since such experiences can be conceptualised to 
index an underlying continuum both cPLEs and cEES were treated as 
continuous variables.  
 
Extent of use was indexed primarily by frequency of cannabis use and by 
potency. In further sensitivity analysis we replaced these with money spent on 
cannabis use and calculated a fourth variable “frequency-potency” where we 
stratified frequency by use of high or low potency (i.e. categories: every day 
high potency; every day low potency; more than once a week high potency; 
more than once a week low potency; a few times a month high potency; a few 
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times a month low potency; a few times each year high potency; a few times 
each year low potency; only once or twice high potency; only once or twice 
low potency). We calculated Pearson’s Correlation coefficients to test whether 
the four extent of use variables were correlated. 
 
Demographics and substance use: We ascertained differences between 
demographic (age at assessment, sex, ethnicity, years in education, site) and 
cannabis use parameters (age of first use, frequency of use, money spent per 
week, potency, duration of use, lifetime and 12 month dependence) and other 
drug use parameters (cigarettes per day, units of alcohol in a day, and other 
drugs ever used (excluding cannabis, alcohol, tobacco and caffeine)) using t-
tests for continuous variables and chi-squared for categorical variables. 
 
Main Analysis:  
We undertook to test the three hypotheses in a regression analyses 
framework. To test hypothesis (a) that caseness predicts experience: we 
regressed cannabis experiences (cPLEs and cEEs) as the dependent 
variables and caseness as the independent variables. To test hypothesis (b) 
that extent of use predicts experiences: we regressed cannabis experiences 
as the dependent variables and the extent of use variables as the 
independent variables. As the extent of use variables we entered frequency of 
cannabis use, and THC potency into separate models. These two variables 
(frequency of use and potency) were chosen to primarily index extent of use 
as they are both related to the extent of cannabis exposure but are distinct 
behaviours (for example one can use very frequently but at low potency). To 
test hypothesis (c): that there is an interaction between caseness and extent 
of use on cannabis experiences: we regressed cannabis experiences as the 
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dependent variables and  caseness and the extent of use variables alongside 
the interaction of caseness x extent of use. In all models we entered cPLEs as 
a regressor when the dependent variable was cEEs and cEEs as a regressor 
when the dependent variable was cPLEs to ensure that the predictors 
identified for relationships were independent of the other experience. 
 
In sensitivity analyses for hypothesis (b) and (c) we ran the same regressions 
models using money spent on cannabis use and frequency-potency as the 
extent of cannabis use variables rather than the frequency or potency 
variables. 
 
We undertook a further sensitivity analysis to adjust for confounders. 
Psychotic like experiences may be explained by a number of putative other 
confounders other than caseness or extent of use. We hence adjusted for 
firstly demographic variables (age, sex, ethnicity) in secondary models and 
further to this substance misuse confounders in tertiary models (number of 
other drugs used, tobacco use and alcohol use) as other substance misuse 
may arguably be related to cannabis induced experiences to see if interaction 
effects survived putative confounders.  
 
cPLEs and cEEs demonstrated positive skew (cEEs 0.612, cPLEs 2.231). 
Because of violations of homoscedasticity in regression models we undertook 
all analyses using the robust regression option in STATA. For the purpose of 
estimation of 95% Confidence Intervals in figures (see Figure 1 &2)  we 
applied bootstrapping to inferential tests using 1000 samples and bias 
corrected and accelerated confidence intervals. 
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Missing data: Missing data rates are shown in Supplementary Table 4. cPLEs 
were available for 598/655 (91.3%) cases and 615/654 (94.0%) controls 
whereas cEEs scores were available for 602/655 (91.9%) cases and 616/654 
(94.2%) controls.To ensure that results were not the result of systematic 
missing data, missing data was imputed using imputation analysis with 
chained equations(26) for cPLEs and and cEEs as outcome variables, 
independent and auxillary variables. 29 variables were included in the 
imputation model, including cannabis use variables (age of first use, social 
use, frequency, money spent, diagnosis of misuse), other drug use variables 
(tobacco use, alcohol use, number of other drugs used), and demographic 
variables (sex, age, ethnicity, site, psychosis diagnosis). Fifty datasets were 
imputed with 10 cycles.  
 
Regression and main analyses were run using the imputed dataset to account 
for missing data. Exploratory pairwise correlation between the extent of use 
variables was undertaken listwise since pairwise correlation is not available 
using the mi estimate command in STATA. Data was analysed using STATA 
version 15.  
 
Results  
 
Data were available for 1035 cases patients and 1382 controls. 655 cases 
(63.3% of all cases) and 654 controls (47.3% of all controls) reported ever use 
of cannabis and data analysis was restricted to them.  
 
Baseline demographics: 
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Cases were significantly more likely than controls to be male, younger and 
have had fewer years of education (see Table 1a). As expected, cases were 
more likely to have started using cannabis younger, more likely to have used 
more frequently, to have used more other drugs, and smoked more cigarettes 
per day (see Table 1b). Detailed diagnostic, ethnicity and site data are 
presented in Supplementary Tables 1-3. 
 
Extent of use: 
As expected the variables indexing extent of use were significantly correlated. 
This was true for both the primary extent of use variables (frequency, potency) 
and secondary extent of use variables (money spent, frequency-potency). 
Frequency of use weakly correlated with dichotomised potency (r=0.121, 
p=0.001). Frequency of use strongly correlated with with money spent on 
cannabis per week (r=0.703, p<0.001) and  frequency-potency (r=0.888, 
p<0.001) whereas potency moderately correlated with money spent on 
cannabis (r=0.211, p<0.001) and frequency-potency (r=0.38, p<0.001). 
Potency-frequency strongly correlated with money spent (p=0.727, p<0.001). 
 
Caseness by frequency of use on cPLEs and cEEs (hypothesis a): 
As hypothesised caseness predicted cPLEs independent of cEEs (b=0.826, 
t=7.86, p<0.001) and predicted cEEs independent of cPLEs (b=0.840, 
t=4.40,p<0.001) such that patients had both more frequent psychotic-like and 
euphoric experiences than controls.  
 
Extent of use as a predictor of cPLEs and cEEs (hypothesis b): 
As hypothesised extent of use predicted cPLEs independent of cEEs whether 
the extent of use variable was frequency of use (b=0.502, t=6.18, p<0.001), or 
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potency (b=0.543, t=2.36, p=0.019) such that increased extent of use 
predicted increased psychotic-like experiences. 
 
Similarly frequency of use predicted cEEs independent of cPLEs (b=2.17, 
t=21.46, p<0.001) but this was not the case with potency (b=0.210, t=0.55, 
p=0.58). 
 
Interaction Effects (hypothesis c): 
Model parameters for caseness by extent of use and their interaction on 
predicting cannabis psychotic-like experiences can be seen in Table 2 and 
caseness x extent of use scores for mean experiences are shown in Figure 1 
and 2.  
 
Caseness x frequency of use on cPLEs: 
There was a significant caseness effect (b=1.354, t=6.20, p=0.001); a 
significant effect for increased frequency of cannabis use (b=0.794, t=4.74, 
p<0.001); and a significant interaction between group and frequency such that 
increasing frequency was associated with increased difference in cPLEs 
between cases and controls (b=0.229, t=3.49, p=0.001).  
 
Caseness x potency on cPLEs: 
There was no significant effect of caseness (p=0.676); but an effect for 
potency such that increased potency was associated with increased cPLEs 
(b=1.241, t=2.28, p=0.023); and a significant interaction for caseness by 
potency (b=0.438, t=2.04, p=0.042).  
 
Caseness x extent of use variables on cEEs: 
There was evidence for increased euphoric experiences as cannabis use 
increased frequency (b=2.152, t=9.44, p<0.001) but not for potency (p=0.935). 
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There was no significant interaction for either frequency or potency of 
cannabis use x caseness for cEEs as the dependent variable.  
 
Sensitivity analysis (hypothesis b): 
For cPLEs results were the same when extent of use was indexed by money 
spent on cannabis per week (b=0.397, t=6.17, p<0.001) and potency by 
frequency (b=-0.412, t=6.15, p<0.001) such that both variables predicted 
increased psychotic-like experiences. Similarly for cEEs increased money 
spent on cannabis predicted cEEs independent of cPLEs (b=1.24, t=13.64, 
p<0.001), as did potency-frequency (b=1.38, t=14.38, p<0.001). 
 
Sensitivity analysis (hypothesis c): 
Caseness x money spent on cPLEs: There was no significant effect of 
caseness (p=0.112); but there was a significant effect for money spent such 
that cPLEs increased with more money spent (b=0.591, t=4.56, p=0.001); and 
a significant interaction between caseness and money spent such that more 
money spent was associated with increased difference in cPLEs between 
cases and controls (b=0.177, t=3.29, p=0.001).  
Caseness x frequency-potency on cPLEs: There was no significant effect of 
caseness (p=0.906); but there was a significant effect for frequency-potency  
such that cPLEs increased with increasing use (b=0.581, t=4.09, p<0.001); 
and an interaction between frequency-potency and caseness (b=0.162, 
t=2.78, p=0.006) such that increasing frequency-potency was associated with 
increased difference in cPLEs between cases and controls.  
Caseness x extent of use variables on cEEs: There was evidence for 
increased euphoric experiences as cannabis use increased for money spent 
(b=1.109, t=5.75, p<0.001) and frequency-potency (b=1.302, t=6.33, 
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p<0.001). There was no significant interaction for any of the extent of use 
variables x caseness for cEEs as the dependent variable.  
 
Sensitivity analysis: Adjustment for demographic and substance use 
covariates: 
In secondary models we adjusted models for cPLEs as the dependent 
variables for demographic covariates: the interaction terms remained 
significant for caseness x frequency of use (b=0.207, t=3.19, p=0.001); 
caseness x money spent on cannabis (b=0.163, t=3.07, p=0.002); caseness x 
potency (b=0.446, t=2.08, p=0.038); and caseness x potency-frequency 
(b=0.43, t=2.48, p=0.013). In tertiary models we additionally adjusted for 
substance misuse covariates: the interaction terms remained significant for 
caseness x frequency of use (b=0.208, t=3.23, p=0.001) and caseness x 
money spent on cannabus (b=0.176, t=3.30, p=0.001); caseness x potency 
(b=0.441, t=2.08, p=0.038); and caseness x potency-frequency (b=0.145, 
t=2.52, p=0.012). We conclude that the caseness x extent of use interaction 
for increased cPLEs for patients versus controls is robust to a number of 
demographic and substance use confounders. 
 
Discussion: 
 
To our knowledge, this represents the largest case-control study with 
extensive cannabis data in First Episode Psychosis ever undertaken. We  (a) 
replicate the finding that cannabis intoxication experiences are more frequent 
in patients compared to controls; (b) show that extent of use as indexed by 
frequency of use and money spent on cannabis per week predict these 
experiences and (c) show that there is an interaction between caseness x 
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frequency and caseness x money spent and caseness x frequency-potency 
such that increasing levels of use are associated with more frequent 
psychotic-like experiences (but not euphoric experiences) in patients 
compared with controls. 
 
Importantly, these findings indicate that cannabis related experiences change 
as a function of extent of use. The Cannabis Experiences Questionnaire 
provides a measure of experiences as a proportion of total cannabis use, 
rather than a simple count of total experiences. A maximal score for cPLEs 
indicates that all six psychotic like experiences were experienced every time 
cannabis was used whereas a minimal score indicates that these experiences 
were never or rarely experienced, irrespective of total number of times used.  
Hence higher scores indicate that the experience changes rather than simply 
indicating an increased total number of experiences due to increased number 
of times that cannabis is used.  
 
This study extends previous work(15) by showing that extent of use is a key 
predictor of psychotic-like experiences and that FEP patients and controls 
have divergent experiences with increasing extent of use. Interestingly, the 
same relationship  does not hold for euphoric experiences as cEEs scores, 
when stratified by extent of use, are well-matched between cases and 
controls. This suggests that specific mechanisms underlie the cannabis-
related increases of psychotic-like experiences which may be related to 
genetic predisposition and may further support a GxE interaction as has been 
demonstrated on cannabis use with the risk of schizophrenia spectrum 
disorder(27). One putative mechanism to be examined is that variation in the 
DRD2 and possibly AKT1 genes may render cases more likely to develop 
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postsynaptic supersensitivity(28,29).  Further work is needed to identify the 
specific genetic mechanisms which interact with increased extent of use.  
 
Strengths and Limitations: 
The particular strengths of this study are (i) the sample size and (ii) the 
international sample. The limitations include: (i) the cross-sectional design, (ii) 
the use of self report measures and (iii) the lack of laboratory tests of potency.  
 
The cross-sectional design precludes interpretation about temporal sequence 
of associations, which means it is difficult to disentangle whether extent of use 
causes enhanced experience or vice-versa.  Euphoric experiences (cEEs) are 
likely to drive use whereas this is not the case for psychotic-like experiences 
(cPLEs) which have previously been shown to be associated with subsequent 
discontinuing use(18,30). Furthermore in the case of cPLEs we included cEEs 
as a covariate in the model to regress out the association with euphoria. This 
may tentatively suggest a role for sensatisation to increasing levels of 
cannabis use for cPLEs in FEP. 
 
Both exposure and outcome measures were based on self-report. There are 
limited methods to determine extent of use over a longer period. Hair samples 
can provide an estimate of use over three months, but have been shown to be 
unreliable in a major observational study(31). Moreover, self-report (but not 
hair) measures of cannabis use were found to predict acute psychotomimetic 
responses to cannabis(32). Additionally, self-reported data on cannabis 
potency is associated with its concentration of THC measured in the 
laboratory(33) The outcome measures, although self-reported, were based on 
a considerable body of work validating cannabis experiences in non-clinical, 
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although not in clinical populations(12,23).  Another limitation is that the 
psychotic-like experiences were rated retrospectively rather than as state 
measures (e.g. in an experimental design administering THC).  
On the other hand, a strength of utilising retrospective self-report measures is 
that these are the experiences patients report to their clinicians during routine 
consultations. There were several differences between cases and controls, 
but the results persisted after adjusting for a wide variety of confounders. 
Perhaps most importantly cEEs were the same  between patients and 
controls when accounted for extent of use: this indicates differences in cPLEs 
between FEP and controls to be specific to intrinsic biological differences 
between groups rather than to other confounders. 
 
Clinical implications: 
We consider this study to have a number of important findings in the clinical 
context. Although easily elicitable, clinicians do not routinely inquire about 
cPLEs in the clinical context. Our study suggests there are important 
differences between FEP patients and controls. Firstly our study adds to 
previous work(15), that patients experience cPLEs more frequently than 
controls. Secondly our work indicates that reduced extent of use is associated 
with decreased cPLEs. This is in line with evidence suggesting that FEP who 
continue to use cannabis, especially daily high potency experience more 
relapses and worse clinical outcome than those who stop after illness 
onset(5). Thirdly we show that FEP patients are unlikely to derive greater 
euphoric effects compared to controls at increased levels of use, despite more 
frequent psychotic-like effects. This suggests that patients and particularly 
those with profound cPLEs should be encouraged to reduce amount and 
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frequency of intake; be advised that for high-potency cannabis there is limited 
evidence of added euphoric effect. 
 
Taken together we have shown that extent of cannabis use is associated with 
enhanced psychotic-like but not euphoric experiences in First Episode 
Psychosis patients compared to controls. Further research should aim to 
determine the biological mechanism underpinning differences between 
patients and controls. 
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Table 1a: Baseline characteristics between cases and controls 
 
 
Case Controls p-Value 
Male 
Missing 
475 (72.5%) 
nil 
355 (54.3%) 
nil 
<0.001 
White 
Missing 
415 (63.6%) 
nil 
547 (83.8%) 
1 (0.2%) 
<0.001 
Age at first 
contact (x ) 
Missing 
28.07 
 
nil 
 
 
Age at 
assessment (x ) 
Missing 
28.51 
 
nil 
34.30 
 
1 (0.2%) 
<0.001 
Years in 
Education 
Missing* 
13.31 
 
12 (1.8%) 
15.69 
 
2 (0.3%) 
<0.001 
 
Table 1b: Comparison of Cannabis use patterns between cases and 
controls 
 
 
Case Controls p-Value 
Age first tried cbs 
(x ) 
 
Missing* 
 
16.91 
 
15 (2.2%) 
 
17.90 
 
nil 
 
<0.001 
Frequency of cbs 
use 
Once or twice 
Few times year 
Few times month 
>Once a week 
Every day 
 
Missing* 
 
 
108 (16.9%) 
65 (10.2%) 
63 (9.8%) 
110 (17.2%) 
294 (45.9%) 
 
15 (2.3%) 
 
 
240 (36.8%) 
120 (18.4%) 
100 (15.3%) 
100 (15.3%) 
93 (14.2%) 
 
1 (0.2%) 
 
 
 
 
 
<0.001 
Money Spent per 
week on cbs 
< €2.50 
€2.50-€5.00 
€6-€10 
€11-€15 
€16-€20 
>€20 
Missing 
 
 
217 (37.0%) 
52 (8.8%) 
80 (13.5%) 
36 (6.1%) 
39 (6.6%) 
170 (28.6%) 
61 (9.3%) 
 
 
415 (68.4%) 
58 (9.6%) 
42 (6.9%) 
25 (4.1%) 
24 (4.0%) 
43 (7.1%) 
47 (7.2%) 
 
 
 
 
 
 
 
<0.001 
Use of high 
potency cbs 
Missing 
 
291 (55.5%) 
131 (20.0%) 
 
223 (43.1%) 
136 (20.8%) 
 
<0.001 
Mean Duration of 
cbs use (years) 
Missing 
9.41 
 
18 (2.7%) 
9.82 
 
28 (4.3%) 
0.418 
Current cbs use 
Missing 
223 (34.2%) 
2 (0.3%) 
151 (23.1%) 
1 (0.2%) 
<0.001 
Lifetime DSM IV 
cbs Dependence 
Missing* 
 
247 (39.3%) 
26 (4.0%) 
 
58 (8.9%) 
3/654 (0.5%) 
 
<0.001 
Last 12 month 
DSM IV cbs 
 
96 (15.0%) 
 
12 (1.8%) 
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Dependence <0.001 
Missing* 26 (5.2%) 3 (0.5%) 
 
Number of other 
drugs tried 
Missing 
 
1.47 
nil 
 
0.97 
nil 
 
<0.001 
Cigarettes/Roll-
ups per day† 
Missing* 
 
10.83 
19 (2.9%) 
 
4.42 
8 (1.2%) 
 
<0.001 
Units of alcohol 
per day† 
Missing 
 
5.14 
143 (21.8%) 
 
5.65 
88 (13.4%) 
0.251 
 
 
Legend: cbs: cannabis; Mean numbers (x  )are given unless specified as a proportion. 
Significance testing undertaken via 2-tailed independent t-tests for continuous variables and 
chi-squared tests for categorical variables. Missing data rates are italicised.  
 
* indicates significant difference (p<0.05) in missing data between cases and controls (chi 
squared test or Fisher’s exact test where any single value <=5).  
† Data was cleaned to remove outliers to max 40 cigarettes/day. Units of alcohol data 
cleaned to max of 30 units day  
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Table 2 Primary Models for cannabis-induced Psychotic-Like Experiences 
caseness x extent of use interaction 
 
 
 (i) Model 1 – Frequency of cannabis use as a predictor F(4,1239.3)=33.65, p<0.001 
 b t p 
Frequency of cannabis use* 0.794 4.74 0.001 
Caseness† 1.354 6.20 <0.001 
Caseness x Frequency of use‡ 0.229 3.49 <0.001 
Cannabis-induced Euphoric Experiences 0.719 3.35 <0.001 
    
 (ii) Model 2 – Potency of cannabis as a predictor F(4,1141.9)=27.02, p<0.001 
 b t p 
Potency of cannabis* 1.241 2.28 0.023 
Caseness 0.142 0.42 0.676 
Caseness x Potency 0.438 2.04 0.042 
Cannabis-induced Euphoric Experiences 0.114 6.43 0.016 
    
 (iii) Model 3 – Money spent  on cannabis as a predictor F(4,1235.8)=33.35, p<0.001 
 b t p 
Money spent on cannabis* 0.591 4.56 <0.001 
Caseness 0.267 1.59 0.112 
Caseness x Money spent on cannabis‡ 0.177 3.29 0.001 
Cannabis-induced Euphoric Experiences 0.084 4.35 <0.001 
    
 (iv) Model 4 – Potency-frequency as a predictor F(4,1241.1)=33.04, p<0.001 
 b t p 
Potency-frequency* 0.581 4.09 <0.001 
Caseness 0.030 0.12 0.906 
Caseness x Potency-frequency‡ 0.162 2.78 0.006 
Cannabis-induced Euphoric Experiences 0.114 6.43 <0.001 
    
 
Legend: 
Directions of effect as follows: *Increased extent predicts increased cPLEs; †First Episode Psychosis 
predicts increased cPLEs; ‡Significant caseness x estent interaction 
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Figure 1: Mean cannabis-induced Psychotic-like Experiences and Euphoric 
Experiences scores by case and control
1
 
 
(a-b) Caseness x Frequency of cannabis use interaction on cannabis-induced experiences: 
 
  
 
(c-d) Caseness x Money spent on cannabis per week interaction on cannabis-induced experiences: 
 
  
 
(e-f) Caseness x  Potency of cannabis used interaction on cannabis-induced experiences : 
 
                                                       
Legend: Blue bars indicate First Episode Psychosis cases, red bars for controls. Data drawn from complete case 
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Figure 2: Mean cannabis-induced Psychotic-like Experiences and Euphoric 
Experiences scores by case and control
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(a) Caseness x Frequency x Potency interaction on psychotic-like experiences: 
 
 
 
 
(b) Caseness x Frequency x Potency interaction on euphoric experiences: 
 
 
 
 
 
                                                       
Legend: Blue bars indicate First Episode Psychosis cases, red bars for controls. Data drawn from complete case 
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